CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
ferric citratedrug
Likely dose
ferric citrate 375mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00648167
NCT00648167Phase 2Completed
CompareCT.gov

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

Keryx Biopharmaceuticals·interventional·Posted Apr 1, 2008·Updated Apr 4, 2017

In Brief

A Phase 2 clinical trial evaluating ferric citrate for Hyperphosphatemia and End-stage Renal Disease. Completed, enrolled 55 participants across 1 site.

Detailed Summary

This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphatemia, End-stage Renal Disease
CountriesUnited States
CollaboratorsCollaborative Study Group (CSG)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 1, 2008
Enrollment StartMar 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.3 years ago

Interventions

ferric citratedrug

ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.